SOX2 and oropharynx cancer: Three markers, PD-1, PD-L1 and CTLA-4, related to immune therapy were not significantly different according to SOX2 expression in either HPV+ or HPV− oropharyngeal cancers (all p > 0.05) (Figure S8).